TrialFrontiers in immunology2020

Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.

Jui-Cheng Tseng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.